BRPI1013428A2 - anticorpos humanizados para axl - Google Patents

anticorpos humanizados para axl

Info

Publication number
BRPI1013428A2
BRPI1013428A2 BRPI1013428A BRPI1013428A BRPI1013428A2 BR PI1013428 A2 BRPI1013428 A2 BR PI1013428A2 BR PI1013428 A BRPI1013428 A BR PI1013428A BR PI1013428 A BRPI1013428 A BR PI1013428A BR PI1013428 A2 BRPI1013428 A2 BR PI1013428A2
Authority
BR
Brazil
Prior art keywords
axl
humanized antibodies
humanized
antibodies
bind
Prior art date
Application number
BRPI1013428A
Other languages
English (en)
Inventor
Ruhe Jens
Wirtz Peter
Takizawa Takeshi
Takayama Tomoko
Original Assignee
U3 Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP09006355A external-priority patent/EP2270053A1/en
Application filed by U3 Pharma Gmbh filed Critical U3 Pharma Gmbh
Publication of BRPI1013428A2 publication Critical patent/BRPI1013428A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Food Science & Technology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

anticorpos humanizados para axl a presente invenção refere-se a anticorpos monoclonais humanizados que se ligam ao domínio extracelular de axl e pelo menos parcial- 5 mente inibam a atividade de axl.
BRPI1013428A 2009-05-11 2010-05-11 anticorpos humanizados para axl BRPI1013428A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09006355A EP2270053A1 (en) 2009-05-11 2009-05-11 Humanized AXL antibodies
EP09006474 2009-05-13
PCT/EP2010/056487 WO2010130751A1 (en) 2009-05-11 2010-05-11 Humanized axl antibodies

Publications (1)

Publication Number Publication Date
BRPI1013428A2 true BRPI1013428A2 (pt) 2019-07-02

Family

ID=42272537

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1013428A BRPI1013428A2 (pt) 2009-05-11 2010-05-11 anticorpos humanizados para axl

Country Status (15)

Country Link
US (2) US8841424B2 (pt)
EP (1) EP2430050A1 (pt)
JP (2) JP5909442B2 (pt)
KR (1) KR20120035145A (pt)
CN (1) CN102421802B (pt)
AR (1) AR076564A1 (pt)
AU (1) AU2010247464B2 (pt)
BR (1) BRPI1013428A2 (pt)
CA (1) CA2759836A1 (pt)
IL (1) IL216147A (pt)
MX (1) MX2011011825A (pt)
RU (2) RU2571224C2 (pt)
TW (2) TWI526223B (pt)
WO (1) WO2010130751A1 (pt)
ZA (1) ZA201107529B (pt)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI1013428A2 (pt) * 2009-05-11 2019-07-02 U3 Pharma Gmbh anticorpos humanizados para axl
EP2483289B2 (en) 2009-10-02 2025-03-26 Biogen MA Inc. Methods of preventing and removing trisulfide bonds
US9562252B2 (en) 2011-05-13 2017-02-07 Biogen Ma Inc. Methods of preventing and removing trisulfide bonds
AU2012273954A1 (en) * 2011-06-22 2014-01-09 Inserm (Institut National De La Sante Et De La Recherche Medicale) Anti-Axl antibodies and uses thereof
EP2723377B1 (en) * 2011-06-22 2018-06-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-axl antibodies and uses thereof
EP2589609A1 (en) 2011-11-03 2013-05-08 Pierre Fabre Medicament Antigen binding protein and its use as addressing product for the treatment of cancer
US9879061B2 (en) 2011-12-15 2018-01-30 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of AXL/GAS6 signaling in the treatment of liver fibrosis
TWI609887B (zh) * 2012-11-05 2018-01-01 皮爾法伯製藥公司 新穎的抗原結合蛋白及其作爲治療癌症之定址產物的用途
ES2665323T7 (es) 2012-12-14 2023-06-15 Univ Leland Stanford Junior Péptidos de AXL modificados y su uso en la inhibición de la señalización de AXL en terapia anti-metastásica
WO2016091891A1 (en) * 2014-12-09 2016-06-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Human monoclonal antibodies against axl
CN116410318A (zh) 2014-12-18 2023-07-11 卑尔根技术锻造股份公司 抗axl拮抗抗体
GB201506411D0 (en) * 2015-04-15 2015-05-27 Bergenbio As Humanized anti-axl antibodies
WO2016187356A1 (en) * 2015-05-18 2016-11-24 Agensys, Inc. Antibodies that bind to axl proteins
WO2016187354A1 (en) 2015-05-18 2016-11-24 Agensys, Inc. Antibodies that bind to axl proteins
GB201509338D0 (en) 2015-05-29 2015-07-15 Bergenbio As Combination therapy
KR20180033523A (ko) 2015-07-10 2018-04-03 젠맵 에이/에스 암 치료를 위한 axl-특이적 항체-약물 접합체
MY194586A (en) 2015-09-24 2022-12-05 Daiichi Sankyo Co Ltd Anti-garp antibody
AU2017248644B2 (en) 2016-04-15 2019-10-31 Bioatla, Llc Anti-Axl antibodies, antibody fragments and their immunoconjugates and uses thereof
GB201610902D0 (en) 2016-06-22 2016-08-03 Bergen Teknologioverforing As And Bergenbio As Anti-Axl Antagonistic Antibodies
MX2019012464A (es) 2017-04-20 2019-12-11 Adc Therapeutics Sa Terapia combinada con un conjugado de anticuerpo y farmaco anti-axl.
CN110540592B (zh) 2018-05-29 2022-08-09 杭州尚健生物技术有限公司 结合axl蛋白的抗体及其应用
CN109160941B (zh) * 2018-09-29 2020-09-04 未名生物医药有限公司 蛋白序列17e11及其用途
RU2678569C1 (ru) * 2018-10-31 2019-01-30 Гордейчук Владимир Евгеньевич Способ подавления метастазирования опухолей
GB201912059D0 (en) 2019-08-22 2019-10-09 Bergenbio As Combaination therapy of a patient subgroup
CN110982791A (zh) * 2019-12-26 2020-04-10 百泰生物药业有限公司 一种分泌axl抗体的杂交瘤细胞的制备筛选方法
EP4087657A1 (en) 2020-01-08 2022-11-16 Synthis Therapeutics, Inc. Alk5 inhibitor conjugates and uses thereof
GB202004189D0 (en) 2020-03-23 2020-05-06 Bergenbio As Combination therapy
US20230250169A1 (en) 2020-04-08 2023-08-10 Bergenbio Asa AXL Inhibitors for Antiviral Therapy
GB202006072D0 (en) 2020-04-24 2020-06-10 Bergenbio Asa Method of selecting patients for treatment with cmbination therapy
AU2022211971A1 (en) 2021-01-29 2023-08-10 Illimis Therapeutics, Inc. Fusion molecule having non-inflammatory phagocytosis inducing activity
GB202104037D0 (en) 2021-03-23 2021-05-05 Bergenbio Asa Combination therapy
CN115927243A (zh) * 2022-09-13 2023-04-07 中山大学 一种akt1蛋白的抑制性磷酸化位点及其应用
CN116715774B (zh) * 2023-05-12 2023-11-24 武汉爱博泰克生物科技有限公司 针对人axl的兔单克隆抗体及其制备方法和应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4931385A (en) * 1985-06-24 1990-06-05 Hygeia Sciences, Incorporated Enzyme immunoassays and immunologic reagents
DE3900534A1 (de) 1989-01-10 1990-07-12 Boehringer Mannheim Gmbh Diagnostischer nachweis unter verwendung von chimaeren antikoerpern
US5468634A (en) * 1991-06-24 1995-11-21 The University Of North Carolina At Chapel Hill Axl oncogene
ATE303161T1 (de) * 1996-03-20 2005-09-15 Immunomedics Inc Humanisierung von anti-carcinoembryonalen antigen anti-idiotypischen antikörper und dessen verwendung als tumorvakzin und zur markierung
EP1190061A1 (en) 1999-06-07 2002-03-27 Neorx Corporation Streptavidin expressed gene fusions and methods of use thereof
EP1382969A1 (en) * 2002-07-17 2004-01-21 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Diagnosis and prevention of cancer cell invasion
HN2004000285A (es) 2003-08-04 2006-04-27 Pfizer Prod Inc ANTICUERPOS DIRIGIDOS A c-MET
JP2008504002A (ja) 2003-11-12 2008-02-14 バイオジェン・アイデック・エムエイ・インコーポレイテッド 新生児Ｆｃレセプター（ＦｃＲｎ）結合ポリペプチド改変体、ダイマーＦｃ結合タンパク質、およびそれらに関連する方法
DE602005026219D1 (de) * 2004-10-01 2011-03-17 Max Planck Gesellschaft Gegen das säugetier-eag1-ionenkanalprotein gerichtete antikörper
ES2707284T3 (es) 2005-03-08 2019-04-03 Pfizer Prod Inc Composiciones de anticuerpo anti-CTLA-4
WO2006105062A2 (en) 2005-03-29 2006-10-05 Verenium Corporation Altered antibody fc regions and uses thereof
AU2006255415B2 (en) 2005-06-07 2011-10-06 Esbatech, An Alcon Biomedical Research Unit Llc Stable and soluble antibodies inhibiting TNFalpha
US20090087431A1 (en) 2007-07-02 2009-04-02 Wyeth Methods of treating bone disorders with modulators of axl
EP2219671A4 (en) * 2007-11-09 2011-02-09 Salk Inst For Biological Studi USE OF TAM RECEPTOR INHIBITORS AS IMMU ENHANCERS AND TAM ACTIVATORS AS IMMUNOSUPPRESSORS
CN101939336B (zh) * 2007-11-12 2014-05-14 U3制药有限公司 Axl抗体
BRPI1013428A2 (pt) * 2009-05-11 2019-07-02 U3 Pharma Gmbh anticorpos humanizados para axl

Also Published As

Publication number Publication date
US20120117670A1 (en) 2012-05-10
IL216147A (en) 2016-04-21
AU2010247464A1 (en) 2011-11-10
AU2010247464B2 (en) 2014-09-11
EP2430050A1 (en) 2012-03-21
JP2016011306A (ja) 2016-01-21
TW201509431A (zh) 2015-03-16
CA2759836A1 (en) 2010-11-18
TW201105348A (en) 2011-02-16
JP5909442B2 (ja) 2016-04-26
RU2011150183A (ru) 2013-06-20
MX2011011825A (es) 2011-12-06
WO2010130751A1 (en) 2010-11-18
KR20120035145A (ko) 2012-04-13
US8841424B2 (en) 2014-09-23
US20150037323A1 (en) 2015-02-05
RU2571224C2 (ru) 2015-12-20
AR076564A1 (es) 2011-06-22
JP2012526530A (ja) 2012-11-01
IL216147A0 (en) 2012-01-31
RU2015147287A (ru) 2017-05-12
CN102421802A (zh) 2012-04-18
ZA201107529B (en) 2012-06-27
CN102421802B (zh) 2014-08-20
TWI526223B (zh) 2016-03-21

Similar Documents

Publication Publication Date Title
BRPI1013428A2 (pt) anticorpos humanizados para axl
CR20170251A (es) Anticuerpos anti-c5 y métodos para su uso
CY1121349T1 (el) Συζευγματα αντισωματων πυρρολοβενζοδιαζεπινης
CR20120577A (es) Anticuerpos hacia gdf8 humano
CL2014000574A1 (es) Anticuerpo monoclonal humanizado que se une al complejo aßtcr/cd3 humano.
CR20150054A (es) Anticuerpos anti-cxcr5 humanizados derivados de los mismos y su uso
NZ586754A (en) Composition comprising antibody that binds to domain ii of her2 and acidic variants thereof
CR20110559A (es) Anticuerpos específicos para cadherina-17
EP2501724A4 (en) MONOCLONAL ANTIBODIES AND DIAGNOSTIC USES THEREOF
CO7020875A2 (es) Anticuerpos humanizados que reconocen la alfa-sinucleina
BR112016000666A2 (pt) Constructos de ligação de antígeno cd3 e cd19 biespecíficos
CR20140146A (es) Anticuerpos anti-cd134 (ox40) y usos de los mismos
CO7111294A2 (es) Anticuerpo anti-fgfr2
PL3181581T3 (pl) Przeciwciała o zmodyfikowanym powinowactwie do FcRn, które wspomagają klierens antygenu
HN2006015949A (es) Anticuerpos de p-caderina
CU24446B1 (es) Un anticuerpo monoclonal humanizado que se une a tau
CO6280499A2 (es) Anticuerpos monoclonales, los cuales enlazan al dominio extracelular del receptor axl de tirosina quinasa y los cuales por lo menos parcialmente inhiben la actividad axl
CO6551674A2 (es) Anticuerpos anti-her3 y usos de los mismo
IL229618B (en) Isolated antibody that binds fcrn
EP2324359A4 (en) MONOCLONAL ANTIBODY STRO-4
SMT201400184B (it) Anticorpi monoclonali che legano b7h6 e loro usi
CO6690763A2 (es) Anticuerpo específico de miostatina y composiciones que lo contienen
HRP20181645T1 (hr) Monoklonalna antitijela prema progastrinu i njihove upotrebe
CR11465A (es) Anticuerpos bivalentes biespecificos
EP2254911A4 (en) HUMANIZED ANTI-C5aR ANTIBODIES

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 8A E 9A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2531 DE 09-07-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B350 Update of information on the portal [chapter 15.35 patent gazette]